Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- PMID: 19423728
- PMCID: PMC2927090
- DOI: 10.1182/blood-2008-12-195792
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Abstract
Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow. Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear. Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL). PD-1(+) TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1(-) TIL and T cells in the normal tissues and PBL. Moreover, PD-1(+) TIL were primarily HLA-DR(+) and CD127(-), in contrast to PD-1(-) TIL. Effector cytokine production by PD-1(+) TIL was impaired compared with PD-1(-) TIL and PBL. Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function. These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.
Figures
Comment in
- Immunotherapy. 2009 Nov;1(6):921-4
-
Blocking PD-1 in cancer immunotherapy.Blood. 2009 Aug 20;114(8):1457-8. doi: 10.1182/blood-2009-05-223412. Blood. 2009. PMID: 19696208
Similar articles
-
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8. Cancer Immunol Res. 2015. PMID: 25957117
-
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.Clin Cancer Res. 2011 Sep 1;17(17):5736-47. doi: 10.1158/1078-0432.CCR-11-0230. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750202
-
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23. Gastroenterology. 2017. PMID: 28648905
-
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260. Epub 2016 May 22. J Immunol Res. 2016. PMID: 27314056 Free PMC article. Review.
-
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.Cancer Immun. 2009 Apr 2;9:3. Cancer Immun. 2009. PMID: 19338264 Free PMC article. Review.
Cited by
-
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.Front Immunol. 2022 Oct 13;13:871076. doi: 10.3389/fimmu.2022.871076. eCollection 2022. Front Immunol. 2022. PMID: 36311748 Free PMC article. Review.
-
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.Sci Transl Med. 2013 Feb 13;5(172):172ra20. doi: 10.1126/scitranslmed.3004888. Sci Transl Med. 2013. PMID: 23408053 Free PMC article.
-
Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma.Onco_target. 2016 Oct 25;7(43):69749-69759. doi: 10.18632/onco_target.11949. Onco_target. 2016. PMID: 27626174 Free PMC article.
-
_targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.Curr Opin Immunol. 2012 Apr;24(2):207-12. doi: 10.1016/j.coi.2011.12.009. Epub 2012 Jan 9. Curr Opin Immunol. 2012. PMID: 22236695 Free PMC article. Review.
-
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy.Cancer Res. 2022 Dec 16;82(24):4641-4653. doi: 10.1158/0008-5472.CAN-22-0112. Cancer Res. 2022. PMID: 36219677 Free PMC article.
References
-
- Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336–347. - PubMed
-
- Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. - PubMed
-
- Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239–245. - PubMed
-
- Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–151. - PubMed
-
- Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–322. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials